Massachusetts H4950 aims to ensure insulin affordability by capping costs and expanding access to assistance programs.
Massachusetts H4950 introduces measures to make insulin more affordable and accessible. It mandates that insurers and health maintenance organizations cap the cost of insulin at $100 for a 30-day supply. The bill also requires pharmaceutical companies to offer a one-time, no-cost supply of insulin to those who urgently need it and meet financial eligibility criteria. Additionally, it establishes procedures for ensuring that insulin patient assistance programs are available to those who qualify. Non-compliance with these provisions could result in fines of $100,000 per month.
Included in complete analysis
- Overview
- Core Provisions
- Implementation
- Impact
- Legal Framework
- Critical Issues
See what it does, who it affects, and the critical issues in plain language. Free, 30 seconds.